Financial burden for radiotherapy patients in Italy
Official title: Valutazione Della "Financial Toxicity" Nei Pazienti Sottoposti a Radioterapia: Uno Studio Multicentrico Italiano Promosso da yAIRO (Associazione Italiana Radioterapia e Ocologia Clinica)
Run by University of Campania Luigi Vanvitelli · NCT07175350 · Data updated 2026-11-12
This project will use a short Italian questionnaire to see if people getting radiotherapy in Italy face financial problems before, during, and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Campania Luigi Vanvitelli Academic / other |
| Locations | 7 sites (Barletta and 6 other locations) |
| Status | Recruiting |
| Started | September 6, 2024 |
| Main results expected | December 1, 2025 |
| Study ends | June 1, 2026 |
| Registry record updated | September 16, 2025 |
| Trial ID | NCT07175350 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a histologically confirmed malignancy who are scheduled to receive radiotherapy at one of the participating Italian centers and who are willing and able to complete the PROFFIT questionnaire.
✕Probably not a fit
Patients under 18, those not receiving radiotherapy, or those who refuse or are unable to complete the questionnaire are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational study using the validated Italian PROFFIT questionnaire to measure financial toxicity in adults receiving radiotherapy for cancer. Participants complete the PROFFIT at baseline (before radiotherapy), at the end of treatment, and at the first follow-up visit (1–2 months after treatment). The study compares financial toxicity across groups defined by cancer type, radiotherapy type and treatment details, age, and sex. Exploratory analyses will look for correlations between changes in financial toxicity and quality of life, patient-reported toxicity, and overall survival.
Why it matters
Potential benefit: If successful, the study could identify which patients are most at risk of financial hardship from radiotherapy and inform targeted support or policy changes.
How similar studies have gone: The PROFFIT questionnaire has been validated in the Italian context and other oncology financial-toxicity instruments have shown usefulness, but longitudinal multicenter data focused on radiotherapy patients remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients older than 18 years of age. Histological diagnosis of malignancy for which the patient requires radiotherapy treatment. Exclusion Criteria: * Patient refusal to complete the questionnaire.
Where it's running
-
Radioterapia Oncologica - Ospedale Mons. Dimiccoli
Barletta, Italy Recruiting -
Unità di Radioterapia - Responsible Research Hospital
Campobasso, Italy Recruiting -
Radioterapia oncologica - Ospedale "Vito Fazzi" -
Lecce, Italy Recruiting -
AOU "L. Vanvitelli" - UOC Radioterapia
Naples, Italy Recruiting -
.C. Radioterapia - INT G. Pascale
Naples, Italy Recruiting -
Radioterapia Oncologica, IRCCS-CROB
Potenza, Italy Recruiting
Show 1 more location
-
UOC Radioterapia - Fondazione Policlinico A. Gemelli
Roma, Italy Recruiting
Study contacts
- Principal investigator: Roberta Grassi, MD — AOU "L. Vanvitelli" - UOC Radioterapia
- Study coordinator: Roberta Grassi, MD
- Email: grassi.roberta89@gmail.com
- Phone: 3333385815
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
-
My Care My Voice: helping patients and clinicians start palliative care conversations
This program tries to help oncologists, hospital staff, and adults with advanced cancer start timely palliative care conversations using brief materials and simple workflow changes in three Belgian hospitals.
-
Muscle Deterioration in Hospitalized Cancer Patients
A study test to see how muscle loss progresses in adults with cancer who are in the hospital and to help identify who might need muscle-support therapies.
-
Metamizole (Optalgin) impact on anti‑Xa levels in cancer patients on apixaban or rivaroxaban
This study will test whether taking metamizole (Optalgin) changes anti‑Xa blood levels in adults with cancer who are taking apixaban or rivaroxaban.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.